NZ588749A - On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors - Google Patents

On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Info

Publication number
NZ588749A
NZ588749A NZ588749A NZ58874908A NZ588749A NZ 588749 A NZ588749 A NZ 588749A NZ 588749 A NZ588749 A NZ 588749A NZ 58874908 A NZ58874908 A NZ 58874908A NZ 588749 A NZ588749 A NZ 588749A
Authority
NZ
New Zealand
Prior art keywords
group
cancer
independently selected
alkyl
chemotherapeutic agent
Prior art date
Application number
NZ588749A
Other languages
English (en)
Inventor
Antonio Jimeno
Manuel Medina Hidalgo
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Priority to NZ588749A priority Critical patent/NZ588749A/en
Publication of NZ588749A publication Critical patent/NZ588749A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ588749A 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors NZ588749A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ588749A NZ588749A (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ588749A NZ588749A (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (1)

Publication Number Publication Date
NZ588749A true NZ588749A (en) 2012-06-29

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588749A NZ588749A (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Country Status (10)

Country Link
US (2) US8962614B2 (OSRAM)
EP (1) EP2271339A4 (OSRAM)
JP (1) JP5479453B2 (OSRAM)
KR (1) KR101707669B1 (OSRAM)
CN (1) CN102056607B (OSRAM)
AU (1) AU2008354754B2 (OSRAM)
CA (1) CA2721722C (OSRAM)
NZ (1) NZ588749A (OSRAM)
RU (1) RU2476239C2 (OSRAM)
WO (1) WO2009128805A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056607B (zh) * 2008-04-17 2014-07-30 约翰·霍普金斯大学 On01910.na促进在抗药性肿瘤中化学治疗剂的活性
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
HUE052968T2 (hu) 2014-04-30 2021-05-28 Fujifilm Corp Liposzóma kompozíció és annak elõállítási eljárása
CA3134991A1 (en) * 2015-02-25 2016-09-01 Bioneer Corporation Pharmaceutical composition for treating cancer comprising microrna as active ingredient
CN107922456A (zh) * 2015-08-28 2018-04-17 浙江海正药业股份有限公司 磷酸氟达拉滨的晶型及其制备方法和用途
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
AU2019288048B2 (en) * 2018-06-20 2022-08-11 Fujifilm Corporation Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
PL4048284T4 (pl) * 2019-10-21 2025-11-03 Acura Nanomedicine Corporation Metoda leczenia nowotworów
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
AU2005317047A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
CA2593523C (en) * 2005-01-05 2014-04-08 Temple University - Of The Commonwealth System Of Higher Education Treatment of drug-resistant proliferative disorders
US7504513B2 (en) * 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
JP5278968B2 (ja) * 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
EP2073803B1 (en) * 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
CN102056607B (zh) * 2008-04-17 2014-07-30 约翰·霍普金斯大学 On01910.na促进在抗药性肿瘤中化学治疗剂的活性

Also Published As

Publication number Publication date
US20110201675A1 (en) 2011-08-18
CA2721722C (en) 2015-12-08
CN102056607A (zh) 2011-05-11
AU2008354754A1 (en) 2009-10-22
JP5479453B2 (ja) 2014-04-23
KR101707669B1 (ko) 2017-02-16
US20150209381A1 (en) 2015-07-30
US8962614B2 (en) 2015-02-24
CN102056607B (zh) 2014-07-30
KR20100137570A (ko) 2010-12-30
EP2271339A4 (en) 2011-09-28
CA2721722A1 (en) 2009-10-22
JP2011518153A (ja) 2011-06-23
WO2009128805A1 (en) 2009-10-22
RU2476239C2 (ru) 2013-02-27
EP2271339A1 (en) 2011-01-12
US9545418B2 (en) 2017-01-17
RU2010145048A (ru) 2012-05-27
AU2008354754B2 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
US9545418B2 (en) ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
ES2877629T3 (es) Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
US12083136B2 (en) Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
KR20180054793A (ko) 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법
JP7596323B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
US11491168B2 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US20210275521A1 (en) Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
TW202317128A (zh) 治療化療相關的胃腸道副作用的化合物和方法
US10434086B2 (en) Combination therapies with curaxins
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202421B (en) Combination therapy with an antitumor antibiotic
HK1188572B (en) Combination therapy with an antitumor alkaloid

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170331

LAPS Patent lapsed